Medtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years

TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial DUBLIN and SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced four-year…

Click here to view original post